Treatment of Wegener's granulomatosis

Michael J. Regan, David B. Hellmann, John H. Stone

Research output: Contribution to journalArticlepeer-review

Abstract

The two principal aims in the treatment of Wegener's granulomatosis (WG) are to limit the extent and severity of permanent organ damage by controlling the disease promptly and to minimize the short- and long-term morbidity that often results from therapy. Remission is considered to be the absence of disease activity in any organ system. Once the disease has been controlled by the initial treatment regimen, which is dictated by the degree of disease severity, the focus of therapy shifts to maintaining disease remission, often with medications less toxic than those used to induce remission. The description of WG treatments in terms analogous to cancer chemotherapy (i.e., those designed to induce remissions and those intended to maintain them) is useful in the formulation of current disease management strategies and in the investigation of new therapies for WG.

Original languageEnglish (US)
Pages (from-to)863-886
Number of pages24
JournalRheumatic Disease Clinics of North America
Volume27
Issue number4
DOIs
StatePublished - 2001

ASJC Scopus subject areas

  • Rheumatology

Fingerprint

Dive into the research topics of 'Treatment of Wegener's granulomatosis'. Together they form a unique fingerprint.

Cite this